alexa Effective half-life of 131I in thyroid cancer patients.
Molecular Biology

Molecular Biology

Journal of Cell Science & Therapy

Author(s): North DL, Shearer DR, Hennessey JV, Donovan GL

Abstract Share this page

Abstract The oral administration of radioactive 131I is a standard treatment for thyroid carcinoma. One consideration for this therapy is assuring that other people do not receive significant radiation exposure. In particular, federal and state regulatory authorities stipulate that no individual should receive more than 5 mSv (500 mrem) effective dose-equivalent from the released patient. Patients receiving more than 1.11 GBq (30 mCi) of 131I were traditionally confined as in-patients by regulation until their burdens of radioactivity fell below that level or until the external dose rates were less than 50 microSv (5 mrem) per hour at 1 m. Recent regulatory guidance recommends the use of biological elimination as well as physical decay in calculating the confinement time to keep the effective dose-equivalent to members of the public less than 5 mSv. Analysis of a database of more than 250 administrations of 131I for thyroid cancer shows a median effective half-life of at least 14 h, with substantial variation. Thus, discharge criteria for radiation safety purposes should be calculated on the basis of individual measurements. The release of these patients should not always be as prompt as the guidance indicates. The results also challenge some long-used assumptions regarding iodine excretion in this patient population.
This article was published in Health Phys and referenced in Journal of Cell Science & Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords